EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Evaluation of the clinical characteristics and potentially prognostic factors in HER2-positive breast cancer

Liang Shi, Pei-Wen Xi, Zhi Li, Jing Wu, Xu Zhang, Lei Zhang

Amino Acids · 2025

DOI: 10.1007/s00726-025-03494-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift Amino Acids, 2025. Verfasst von Liang Shi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Breast Disease Center, The First Affiliated Hospital With Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, China. shiliang@njmu.edu.c…. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Biomarkers, Tumor. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Young Scholars Fostering Fund of the First Affiliated Hospital of Nanjing Medical University, National Natural Science Foundation of China, Young Scientist Program of Jiangsu Provincial People's Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

From January 2000 to December 2019, the SEER Plus Database collecting human epidermal growth factor receptor 2 (HER2) and hormone receptor (HR; including estrogen receptor [ER] and progesterone receptor [PR]) status for breast cancer (BC) cases. HER2-positive (HER2+) BC is an aggressive type, and HER2-targeted therapies have significantly improved the therapeutic outcome of patients. However, not every HER2+ BC patient achieves optimal benefits from current HER2-targeted therapies. Here, we conducted a detailed analysis to compare the demographic and clinic-pathological characteristics, survival, differential genes and mutations between HR+ and HR- in HER2+ BC patients. In this retrospective cohort study, Joint HR and HER2 status distributions by more than ten specific clinic-pathological characteristics were evaluated by using Pearson's chi-squared (χ2) test. The transciptome RNA-seqencing (RNA-seq) expression data together with detailed clinic-pathological information of HER2+ BC were from The Cancer Genome Atlas (TCGA) and UCSC Xena. 30,482 (71.02%) patients were identified as HR+ /HER2+ BC and 12,440 (28.98%) patients were identified as HR-/HER2+ BC. HR+ /HER2+ BC patients were more likely to be younger than 50-year-old, white and infiltrating lobular carcinoma history than patients with HR-/HER2+. Patients with HR+ /HER2+ BC had lower risks of breast cancer-specific death and higher overall survival rates. Mast cells were enriched in the HR+ /HER2+ BC group, while plasma cells were more abundant in the HR-/HER2+ BC group.In conclusion, HER2+ BC patients benefit differently from current HER2-directed therapies, maybe partly due to the HR status and gene mutations, and they may provide potentially prognostic and predictive value and new treatment strategies for clinicians.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesBiomarkers, TumorHumansFemaleMiddle AgedPrognosisRetrospective StudiesReceptors, ProgesteroneReceptors, EstrogenAdultAgedMutation

Stichwörter der Autor:innen

Breast cancerClinical characteristicsHER2 positiveHR statusPrognostic factors

Substanzen

Erb-b2 Receptor Tyrosine KinasesReceptors, ProgesteroneReceptors, EstrogenBiomarkers, TumorERBB2 protein, human

Autor:innen und Institutionen

  • Breast Disease Center, The First Affiliated Hospital With Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, China. shiliang@njmu.edu.cn.
  • Health Management Center, The First Affiliated Hospital With Nanjing Medical University, Nanjing, China.
  • Department of Breast and Thyroid Surgery, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu, China.
  • Department of Pathology, The First Affiliated Hospital With Nanjing Medical University, Nanjing, China.
  • Breast Disease Center, The First Affiliated Hospital With Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, China.
  • Department of Gynaecology, Women's Hospital of Nanjing Medical University (Nanjing Women and Children's Healthcare Hospital), 123 Tianfei Xiang, Mochou Road, Nanjing, 210004, China. njsfyzl@163.com.

Förderung

  • Young Scholars Fostering Fund of the First Affiliated Hospital of Nanjing Medical University
  • National Natural Science Foundation of China
  • Young Scientist Program of Jiangsu Provincial People's Hospital

Zitieren

APA

Shi, L., Xi, P. W., Li, Z., Wu, J., Zhang, X., & Zhang, L. (2025). Evaluation of the clinical characteristics and potentially prognostic factors in HER2-positive breast cancer. Amino Acids. https://doi.org/10.1007/s00726-025-03494-x

Vancouver

Shi L, Xi PW, Li Z, Wu J, Zhang X, Zhang L. Evaluation of the clinical characteristics and potentially prognostic factors in HER2-positive breast cancer. Amino Acids. 2025. doi:10.1007/s00726-025-03494-x

BibTeX
@article{Shi2025,
  author = {Shi, Liang and Xi, Pei-Wen and Li, Zhi and Wu, Jing and Zhang, Xu and Zhang, Lei},
  title = {Evaluation of the clinical characteristics and potentially prognostic factors in HER2-positive breast cancer},
  journal = {Amino Acids},
  year = {2025},
  doi = {10.1007/s00726-025-03494-x}
}
Kostenlos starten →